Samarth Kulkarni

Chief Executive Officer & Chairman of the Board

CRISPR Therapeutics

Session

Emerging Tech: Reshaping Entrepreneurship

Start Time:

9:20 AM

Bio

Dr. Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics since 2017. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then was appointed to President and Chief Business Officer before becoming CEO. Prior to joining CRISPR, he was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice and also served as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR Therapeutics and Bayer. Dr. Kulkarni currently serves on the Board of Directors of Centessa Pharmaceuticals and two precision oncology companies, Black Diamond Therapeutics and Repare Therapeutics. He has also served on the Board of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO). He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B.Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research on the delivery of biological drugs and in the field of molecular diagnostics. He has authored several publications in leading scientific and business journals.

Topic:

Ushering in a New Paradigm in Medicine with CRISPR Technology

With new groundbreaking technologies like CRISPR, we have the opportunity to revolutionize medicine by shifting from daily pills and chronic medications toward the vision of one-time treatments. Dr. Samarth Kulkarni will discuss the current state of biotechnology, opportunities for new technologies and business models, and what’s next for the healthcare delivery model of the future. Dr. Kulkarni will talk through his personal journey as well as his experience and lessons learned while leading a fast-growing company at the cutting-edge of technology.